Publicaciones y presentaciones

As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.

Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.

In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.